Emerging therapies for noninfectious uveitis: What may be coming to the clinics

Journal of Ophthalmology

Volumn 2014, Issue , 2014, Pages

  Maya, Jose R ^a   Sadiq, Mohammad A ^a   Zapata, Liz J ^a   Hanout, Mostafa ^a   Sarwar, Salman ^a   Rajagopalan, Nithya ^a   Guinn, Kathleen E ^a   Sepah, Yasir J ^a   Nguyen, Quan Dong ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84901257021     PISSN: 2090004X     EISSN: 20900058     Source Type: Journal    
DOI: 10.1155/2014/310329     Document Type: Review

References (33)

1. Fel A., Aslangul E., Le Jeunne C., Eye and corticosteroid's use. Presse Medicale 2012 41 4 414 421 2-s2.0-84858754006 10.1016/j.lpm.2012.02.001
2. Kruh J., Foster C. S., Corticosteroid-sparing agents: conventional systemic immunosuppressants. Developments in Ophthalmology 2012 51 29 46
3. Truchetet M. E., Mossalayi M. D., Boniface K., IL-17 in the rheumatologist's line of sight. BioMed Research International 2013 2013 18 295132 10.1155/2013/295132
4. + T cells to produce IL-17 in Vogt-Koyanagi-Harada disease. Journal of Allergy and Clinical Immunology 2007 119 5 1218 1224 2-s2.0-34247552894 10.1016/j.jaci.2007.01.010 (Pubitemid 46667160)
5. Chi W., Zhu X., Yang P., Upregulated IL-23 and IL-17 in Behcet patients with active uveitis. Investigative Ophthalmology & Visual Science 2008 49 7 3058 3064
6. Hueber W., Patel D. D., Dryja T., Wright A. M., Koroleva I., Bruin G., Antoni C., Draelos Z., Gold M. H., Durez P., Tak P. P., Gomez-Reino J. J., Foster C. S., Kim R. Y., Samson C. M., Falk N. S., Chu D. S., Callanan D., Nguyen Q. D., Rose K., Haider A., Di Padova F., Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Science Translational Medicine 2010 2 52 2-s2.0-77958072084 10.1126/ scitranslmed.3001107 52ra72
7. Sehgal S. N., Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clinical Biochemistry 1998 31 5 335 340 2-s2.0-0032105481 10.1016/S0009-9120(98)00045-9 (Pubitemid 28385231)
8. Cohen A. E., Assang C., Patane M. A., From S., Korenfeld M., Evaluation of dexamethasone phosphate delivered by ocular iontophoresis for treating noninfectious anterior uveitis. Ophthalmology 2012 119 1 66 73 2-s2.0-84855320097 10.1016/j.ophtha.2011.07.006
9. Issafras H., Corbin J. A., Goldfine I. D., Roell M. K., Detailed mechanistic analysis of gevokizumab, an allosteric anti-il-1beta antibody with differential receptor-modulating properties. Journal of Pharmacology and Experimental Therapeutics 2014 348 1 202 215
10. Iannone F., Lapadula G., The inhibitor of costimulation of T cells: abatacept. Journal of Rheumatology Supplement 2012 89 100 102
11. Navarro-Millán I., Singh J. A., Curtis J. R., Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor. Clinical Therapeutics 2012 34 4 788.e3 802.e3 2-s2.0-84859624578 10.1016/j.clinthera.2012.02.014
12. Reichert J. M., Which are the antibodies to watch in 2012? mAbs 2012 4 1 1 3 2-s2.0-84856800190 10.4161/mabs.4.1.18719
13. Dick A. D., Tugal-Tutkun I., Foster S., Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013 120 4 777 787
14. Nussenblatt R. B., Byrnes G., Sen H. N., Yeh S., Faia L., Meyerle C., Wroblewski K., Li Z., Liu B., Chew E., Sherry P. R., Friedman P., Gill F., Ferris F., A randomized pilot study of systemic immunosuppression in the treatment of age-related macular degeneration with choroidal neovascularization. Retina 2010 30 10 1579 1587 2-s2.0-78650799667 10.1097/IAE.0b013e3181e7978e
15. Krishnadev N., Forooghian F., Cukras C., Wong W., Saligan L., Chew E. Y., Nussenblatt R., Ferris F. III, Meyerle C., Subconjunctival sirolimus in the treatment of diabetic macular edema. Graefe's Archive for Clinical and Experimental Ophthalmology 2011 249 11 1627 1633 2-s2.0-80755190097 10.1007/s00417-011-1694-9
16. Shanmuganathan V. A., Casely E. M., Raj D., Powell R. J., Joseph A., Amoaku W. M., Dua H. S., The efficacy of sirolimus in the treatment of patients with refractory uveitis. British Journal of Ophthalmology 2005 89 6 666 669 2-s2.0-20344366299 10.1136/bjo.2004.048199 (Pubitemid 40780569)
17. Phillips B. N., Wroblewski K. J., A retrospective review of oral low-dose sirolimus (rapamycin) for the treatment of active uveitis. Journal of Ophthalmic Inflammation and Infection 2011 1 1 29 34
18. Nguyen Q. D., Ibrahim M. A., Watters A., Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. Journal of Ophthalmic Inflammation and Infection 2013 3 1, article 32
19. Cavelti-Weder C., Babians-Brunner A., Keller C., Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012 35 8 1654 1662
20. Gül A., Tugal-Tutkun I., Dinarello C. A., Reznikov L., Esen B. A., Mirza A., Scannon P., Solinger A., Interleukin-1 β -regulating antibody XOMA 052 (gevokizumab) in the treatment of acute exacerbations of resistant uveitis of Behçet's disease: an open-label pilot study. Annals of the Rheumatic Diseases 2012 71 4 563 566 2-s2.0-84857922054 10.1136/annrheumdis- 2011-155143
21. Lai T. Y., What's new in uveitis and ocular inflammation? Asia-Pacific Journal of Ophthalmology 2013 2 4
22. Gevokizumab for Active Scleritis,. NCT01835132, http://www. clinicaltrials.gov
23. Furrer E., Berdugo M., Stella C., Behar-Cohen F., Gurny R., Feige U., Lichtlen P., Urech D. M., Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF- α single-chain antibody, upon topical administration to the rabbit eye. Investigative Ophthalmology and Visual Science 2009 50 2 771 778 2-s2.0-59449086444 10.1167/iovs.08-2370
24. Ottiger M., Thiel M. A., Feige U., Lichtlen P., Urech D. M., Efficient intraocular penetration of topical anti-TNF- α single-chain antibody (ESBA105) to anterior and posterior segment without penetration enhancer. Investigative Ophthalmology and Visual Science 2009 50 2 779 786 2-s2.0-59449107918 10.1167/iovs.08-2372
25. Thiel M. A., Wild A., Schmid M. K., Penetration of a topically administered anti-tumor necrosis factor alpha antibody fragment into the anterior chamber of the human eye. Ophthalmology 2013 120 7 1403 1408
26. Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis,. NCT00823173, http://www.clinicaltrials.gov
27. Hazlewood G. S., Barnabe C., Barr S. G., Martin L., Abatacept use after failure of multiple biologic agents in patients with severe rheumatoid arthritis. Journal of Clinical Rheumatology 2012 18 8 416 418
28. Zulian F., Balzarin M., Falcini F., Martini G., Alessio M., Cimaz R., Cimino L., Zannin M. E., Abatacept for severe anti-tumor necrosis factor α refractory juvenile idiopathic arthritis-related uveitis. Arthritis Care and Research 2010 62 6 821 825 2-s2.0-77953108648 10.1002/acr.20115
29. Abatacept in the Treatment of Uveitis,. NCT1279954, http://www. clinicaltrials.gov
30. Horwath-Winter J., Schmut O., Haller-Schober E.-M., Gruber A., Rieger G., Iodide iontophoresis as a treatment for dry eye syndrome. British Journal of Ophthalmology 2005 89 1 40 44 2-s2.0-11144271371 10.1136/bjo.2004.048314 (Pubitemid 40040236)
31. Iontophoresis Delivery of Dexamethasone Phosphate for Non-infectious, Non-necrotizing Anterior Scleritis, Phase 1 Dose-varying Study. NCT01059955, http://www.clinicaltrials.gov
32. Schultz C., Voclosporin as a Treatment for Noninfectious Uveitis. Ophthalmology and Eye Diseases 2013 5 5 10
33. Sepah Y. J., Michelle E. H., Metcalf B., Khwaja A., Channa R., Ibrahim M., Hatef E., Heo J., Hee J. L., Rentiya Z. S., Do D. V., Nguyen Q. D., Voclosporin: a potentially promising therapeutic agent for noninfectious uveitis. Expert Review of Ophthalmology 2011 6 3 281 286 2-s2.0-79959785460 10.1586/eop.11.19